How VCs invest in software companies vs biotech companies

In an early-stage round of financing for a software company, all the investors may dilute the founders by around 15 to 30 percent of the company’s stock. For a typical early-stage pharma or biotech company, investors may dilute the founders at a higher rate—sometimes up to 70 percent—to reflect this risk.